- Open
- 73.00
- High
- 74.50
- Low
- 72.00
- Close
- 74.50
- Change
- -1.00 (-1.35%)
- Volume
- 1,442,200
⌘K
| 28 Apr 2026 | 07:00:11 | Block Listing Six Monthly Return |
| 21 Apr 2026 | 07:00:06 | Avacta data AACR underline AVA6103 profile |
| 14 Apr 2026 | 11:37:07 | Christina Coughlin - In Vivo 2026 Rising Leader |
| 9 Apr 2026 | 07:00:05 | Q1 2026 Business Update |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Avacta Group is a company that is creating innovative cancer treatments and advanced diagnostic tools using its two exclusive technologies - Affimer® biologics and pre|CISION™ targeted chemotherapy for tumors.
| 28 Apr 2026 | 07:00:11 | Block Listing Six Monthly Return |
| 21 Apr 2026 | 07:00:06 | Avacta data AACR underline AVA6103 profile |
| 14 Apr 2026 | 11:37:07 | Christina Coughlin - In Vivo 2026 Rising Leader |
| 9 Apr 2026 | 07:00:05 | Q1 2026 Business Update |
| 7 Jul 2025 | Annual Report and Accounts (to 2024-12-31) | |
| 6 Jul 2024 | Annual Report and Accounts (to 2023-12-31) | |
| 10 Jul 2023 | Annual Report and Accounts (to 2022-12-31) |
Avacta Group is a company that is creating innovative cancer treatments and advanced diagnostic tools using its two exclusive technologies - Affimer® biologics and pre|CISION™ targeted chemotherapy for tumors.
| 8 Apr 2026 | 07:00:09 | Avacta Announces Science Day 2026 |
Lord Fink and Lord Stevens of Ludgate have interests in this issuer
| 8 Apr 2026 | 07:00:09 | Avacta Announces Science Day 2026 |
Lord Fink and Lord Stevens of Ludgate have interests in this issuer
